Calcium and Magnesium Prophylaxis for Oxaliplatin-related Neurotoxicity: is It a Trade-off Between Drug Efficacy and Toxicity?

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Dec 1

PMID 22128117

Citations 9

Authors

Guido Cavaletti

Affiliations

Soon will be listed here.

Citing Articles

Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents.

Katolkar U, Surana S Curr Protein Pept Sci. 2024; 25(10):753-779.

PMID: 38919003 DOI: 10.2174/0113892037307940240606075208.

Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.

Aghili M, Darzikolaee N, Babaei M, Ghalehtaki R, Farhan F, Razavi S J Gastrointest Cancer. 2022; 54(2):467-474.

PMID: 35426033 DOI: 10.1007/s12029-022-00824-0.

Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy.

Lee G, Kim S Molecules. 2016; 21(9).

PMID: 27657026 PMC: 6273821. DOI: 10.3390/molecules21091252.

EXPRESS: Methylcobalamin ameliorates neuropathic pain induced by vincristine in rats: Effect on loss of peripheral nerve fibers and imbalance of cytokines in the spinal dorsal horn.

Xu J, Wang W, Zhong X, Feng Y, Wei X, Liu X Mol Pain. 2016; 12.

PMID: 27306413 PMC: 4956006. DOI: 10.1177/1744806916657089.

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.

Brami C, Bao T, Deng G Crit Rev Oncol Hematol. 2015; 98:325-34.

PMID: 26652982 PMC: 4727999. DOI: 10.1016/j.critrevonc.2015.11.014.

References

Leonard G, Wright M, Quinn M, Fioravanti S, Harold N, Schuler B . Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5:116. PMC: 1266024. DOI: 10.1186/1471-2407-5-116. View

Windebank A, Grisold W . Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008; 13(1):27-46. DOI: 10.1111/j.1529-8027.2008.00156.x. View

Levi F, Misset J, Brienza S, Adam R, Metzger G, Itzakhi M . A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992; 69(4):893-900. DOI: 10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x. View

. CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst. 2009; 14(2):69-71. DOI: 10.1111/j.1529-8027.2009.00214.x. View

Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E . Chemotherapy-induced neuropathy. Curr Treat Options Neurol. 2010; 13(2):180-90. DOI: 10.1007/s11940-010-0108-3. View

Postma T, Heimans J, Muller M, Ossenkoppele G, Vermorken J, Aaronson N . Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9(7):739-44. DOI: 10.1023/a:1008344507482. View

Hughes R . NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?. Nat Clin Pract Neurol. 2008; 4(2):68-9. DOI: 10.1038/ncpneuro0740. View

Argyriou A, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos H . A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008; 34(4):368-77. DOI: 10.1016/j.ctrv.2008.01.003. View

Kim B, Park H, Roh H, Jeong D, Kim B, Park K . Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res. 2010; 19(8):1097-103. DOI: 10.1007/s11136-010-9670-0. View

10.

Khattak M . Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?. Oncologist. 2011; 16(12):1780-3. PMC: 3248777. DOI: 10.1634/theoncologist.2011-0157. View

11.

Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J . Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(32):5078-81. DOI: 10.1200/JCO.2007.11.4645. View

12.

Cavaletti G, Marmiroli P . Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010; 6(12):657-66. DOI: 10.1038/nrneurol.2010.160. View

13.

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P . Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010; 46(3):479-94. DOI: 10.1016/j.ejca.2009.12.008. View

14.

Argyriou A, Bruna J, Marmiroli P, Cavaletti G . Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2011; 82(1):51-77. DOI: 10.1016/j.critrevonc.2011.04.012. View

15.

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C . Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44(11):1507-15. DOI: 10.1016/j.ejca.2008.04.018. View

16.

Cavaletti G, Alberti P, Marmiroli P . Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011; 12(12):1151-61. DOI: 10.1016/S1470-2045(11)70131-0. View